scholarly journals P4379Risks of mortality and hospitalisation in patients with frailty and chronic heart failure: systematic review and meta-analysis

2017 ◽  
Vol 38 (suppl_1) ◽  
Author(s):  
X. Yang ◽  
J. Lupon ◽  
M. Vidan ◽  
C. Ferguson ◽  
P. Gastelurrutia ◽  
...  
2019 ◽  
Vol 25 (6) ◽  
pp. 993-1006 ◽  
Author(s):  
Mandana Moradi ◽  
Fereshteh Daneshi ◽  
Razieh Behzadmehr ◽  
Hosien Rafiemanesh ◽  
Salehoddin Bouya ◽  
...  

2020 ◽  
Vol 40 ◽  
pp. 101218
Author(s):  
Yuan Liao ◽  
Hao Wen ◽  
Shuqi Ge ◽  
Wanhua Zhong ◽  
Yanchang Liang ◽  
...  

2014 ◽  
Vol 20 (7) ◽  
pp. 522-532 ◽  
Author(s):  
Ingrid Hopper ◽  
Rohit Samuel ◽  
Christopher Hayward ◽  
Andrew Tonkin ◽  
Henry Krum

2021 ◽  
Vol 24 (2) ◽  
pp. E327-E332
Author(s):  
Chenxia Wu ◽  
Zhengtian Lv ◽  
Xinyi Li ◽  
Xinbing Zhou ◽  
Wei Mao ◽  
...  

Background: In recent years, galectin-3, an inflammatory marker, has been demonstrated to be closely related to cardiac fibrosis and heart failure. The purpose of this systematic review and meta-analysis is to define galectin-3 in predicting mortality of heart failure. Methods: PubMed, Embase, and the Cochrane Library were searched. A total of 1540 studies were identified, and of these studies, 19 involving 9217 patients were included in our meta-analysis. Results: The diagnostic hazard ratios of galectin-3 in predicting mortality in chronic heart failure patients was 1.13 (95% CI,:1.07-1.21 ) and 2.17 (95% CI:1.27-3.08) in acute heart failure (HF) patients. Conclusions: Our meta-analysis shows that elevated levels of galectin-3 are associated with higher mortality in both acute and chronic heart failure patients.


2021 ◽  
Vol 9 (5) ◽  
Author(s):  
Elodie Charuel ◽  
Thibault Menini ◽  
Sabrina Bedhomme ◽  
Bruno Pereira ◽  
Nathalie Piñol‐Domenech ◽  
...  

2018 ◽  
Vol 99 (12) ◽  
pp. 2570-2582 ◽  
Author(s):  
Katie Palmer ◽  
Kelly-Ann Bowles ◽  
Michelle Paton ◽  
Megan Jepson ◽  
Rebecca Lane

Sign in / Sign up

Export Citation Format

Share Document